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Force Report [1] and the consensus statement (available only
online at http://dx.doi.org/10.1016/j.jval.2013.02.010) [2] produced
by the Consolidated Health Economic Evaluation Reporting Stan-
dards (CHEERS) group. The focus of these documents is on
improving the quality of reporting of economic evaluations of
health care interventions. Economic evaluations represent a
significant proportion of the articles published in Value in Health,
and by publishing these guidance documents, we are lending our
support to the group’s recommendations. The CHEERS group
methodology is consistent with that used to produce similar
consensus statements as part of the CONSORT initiative [3],
which has considered many aspects of the reporting of the
findings of clinical studies.
In addition to Value in Health, the statement is being simulta-
neously published by BMC Medicine, BMJ, Clinical Therapeutics, Cost-
effectiveness and Resource Allocation, The European Journal of Health
Economics, International Journal of Technology Assessment in Health
Care, Journal of Medical Economics, and Pharmacoeconomics, other
journals which frequently publish economic evaluations in our
field. The intention is to stimulate potential authors of health
economic evaluations to aspire to the recommendations outlined
in both the statement and the supporting elaboration document.
The CHEERS group was an ISPOR Good Research Practices
Task Force, established by the Board of Directors in 2009. Value in
Health is committed to publishing all ISPOR Task Force reports,
and the CHEERS elaboration document represents the 40th in the
series. The ISPOR Good Practices for Outcomes Research series (w
ww.ispor.org) has dealt with issues concerning the methodo-
logy of pharmacoeconomics and outcomes research studies in
the areas of comparative effectiveness research, economic evalua-
tion, modeling, observational studies/databases, medication
adherence studies, patient-reported outcomes, preference-based
assessments, and risk-benefit analysis. Although the impact of
ISPOR Task Force reports has never been formally evaluated, they
are among the most widely cited articles published in Value in
Health and collectively generated 175,000 downloads from the
ISPORWeb site in 2012 alone. Therefore, it is likely that task force
recommendations have positively influenced the quality of phar-
macoeconomics and outcomes research studies.
There are also other actions journals can take to improve the
quality of published studies. First, they can be clearer on the
standards to which they expect authors to aspire. In Value in
Health, we recently revised our Guide to Authors (http://www.ispor.
org/publications/value/submit.asp), with the aim of giving moreprecise guidance on the kinds of articles the journal is interested
in. We stressed our interest in publishing more methodological
articles. Indeed, the first two winners of the Value in Health Article
of the Year Award, established in 2009, were both methods
articles. We also gave a clearer statement of the standards we
expect to see in some of the empirical articles we publish. In
particular, we expect articles reporting burden of illness studies
either to demonstrate that they incorporate methodological
advances or to address an important policy issue.
In addition, we expect ‘‘country adaptations,’’ namely, articles
reporting results for a given country using methods similar to
those previously used for other countries, such as an adaptation
of an existing model or an existing quality-of-life instrument, to
make a substantial original contribution to the literature and to
offer insights that will be of use to other researchers wishing to
adapt the analysis to other countries. In the case of economic
modeling studies, a substantial independent contribution would
involve going beyond merely substituting data on the key para-
meters for the second country. It would also include an analysis
of the suitability of the model structure for use in the second
country, a discussion of which model parameters differ greatly
for the second country and whether the policy context was
sufficiently different to require a different interpretation of the
results (e.g., different cost-effectiveness threshold(s), different
perspectives on costs, or different incentive structures for the
adoption of the new intervention). In addition, it would be useful
to discuss what, if anything, can be learned from the model
adaptation that could inform its use in other jurisdictions.
In the case of validations of quality-of-life instruments in a
different jurisdiction, a substantial contribution would involve going
beyond merely translating and back-translating the instrument. It
would also involve a discussion of cultural differences between the
countries that could affect the use or interpretation of the instrument
and whether judgments about the relative weights to be assigned to
changes in different domains, or the assessment of a quantitatively
important change, are likely to differ across settings. As in the case of
the economic modeling studies, it would also be useful to discuss
what—if anything—can be learned from the given country adapta-
tion that could inform adaptations to other jurisdictions.
The second action that journals can take is to improve the
efficiency of their own editorial processes to reduce the burden
on authors and reviewers. In common with many journals in the
health services research field, our online manuscript submission
system is slightly more resource intensive for authors at the time
of submission but assists in managing the editorial task by
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through the various stages of review and to issue reminders to
individuals where there are delays.
Delays in the editorial process are a major concern both to
authors and to journal editors. The central problem is that peer
review is essentially a voluntary activity that has to be accom-
modated alongside the formal job responsibilities of reviewers and
coeditors. Although recognizing that one will never solve the
problems of delays completely, in Value in Health we have taken
several steps to bring about improvements. First, in collaboration
with our coeditors we introduced new reviewing guidelines, with
the aim of speeding up the review process at all stages. For
example, the guidelines encourage coeditors to reject articles
without review if they have reason to believe that the level of
interest or methodological quality of an article is unlikely to meet
the journal’s standards. This avoids wasting reviewers’ time, and
thus they can concentrate on helping the journal improve the
quality of the articles that it publishes. It also provides a faster
response time to authors whose articles are the least likely to
make it through to publication in Value in Health. Second, the
guidelines encourage coeditors to make a decision at the earliest
possible stage, rather than seeking additional reviews, or re-
reviews, which are only likely to be confirmatory. Of course,
despite these measures, some articles (perhaps one of yours!)
are still in the review process longer than the journal would like,
especially in cases where the reviewers are divided on whether or
not the article should be published. Nevertheless, in the past 2
years, the measures we have taken have resulted in an increase in
the proportion of articles rejected without review from 21.7% in
2010 to 35.6% in 2012. For those articles that are sent out to review,
we are continuing our efforts to decrease the time to first decision,
although this is proving more challenging because it requires the
cooperation of reviewers as well as our own editorial team.
We would welcome other suggestions from the journal’s read-
ership and authors on other measures that should be taken to
improve the quality of published articles in pharmacoeconomicsand outcomes research. We recognize that there is a need for
continuous improvements in the quality and transparency of the
peer-review process and are grateful for any help that is offered.
Nevertheless, we remain optimistic about the progress of
research in our field and look forward to publishing even more
outstanding articles in the future.
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